Aurisco, a pharmaceutical company and contract development and manufacturing organization (CDMO) in China, is cooperating with global life sciences company Cytiva, to build its first Oligo FlexFactory platform for commercial production.

The Oligo FlexFactory platform is the first of the three planned commercial manufacturing lines of Aurisco in Yangzhou of East China. The entire manufacturing site is expected to produce 200 kilograms of oligonucleotides every year.

During this cooperation, Cytiva will offer a comprehensive enterprise solution to Aurisco. It includes an Oligo FlexFactory GMP platform and various technical and service support, such as talent training, process design of the manufacturing site, as well as life-cycle project management.